“NATICK, Mass.–(BUSINESS WIRE)–Naveris, Inc., a leader in molecular diagnostics for viral cancers, today announced the presentation of significant new data at the plenary session of the ASTRO 2022 Multidisciplinary Head and Neck Cancers Symposium supporting the clinical value of its flagship diagnostic test, NavDx®.
In a real-world analysis of 1,076 patients treated for HPV-driven head and neck cancer in the surveillance setting across 124 U.S. medical sites, the NavDx blood test accurately identified 80 patients with recurrent cancers, showing an overall positive predictive value of 95%. A positive NavDx test, which measures tumor tissue modified viral HPV DNA (“TTMV-HPV DNA”), was the first indication of recurrence in 72% of these patients, previously considered to be disease-free, in which imaging and/or biopsy subsequent to the positive NavDx test confirmed the presence of recurrence.”
Read the full article at BusinessWire.com.
